Company: AEMD
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001683168-25-002685
Chunk: 18

Company: AETHLON MEDICAL INC
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 18
---
 result from such reverse stock split, will be rounded up to the next whole share.

| 9 |

Approval of Reverse Stock Split of our Common Stock (Proposal 1)

Our Board of Directors has approved and is recommending
that our stockholders approve a Reverse Stock Split of our common stock at a ratio in the range of 1-for-5 to 1-for-12. We are proposing
that our Board of Directors have the discretion to select the Reverse Stock Split ratio from within such range, rather than proposing
that stockholders approve a specific ratio at this time, in order to give our Board of Directors the flexibility to implement a Reverse
Stock Split at a ratio that reflects the Board of Directors’ then-current assessment of the factors described below under “Criteria
to be Used for Determining Whether to Implement the Reverse Stock Split.” If the Board of Directors decides to implement a Reverse
Stock Split, the Board of Directors will do so within a reasonable time following the Special Meeting by resolution (but in no event later
than May 13, 2026), which will include the specific timing and ratio of the Reverse Stock Split. Except for adjustments that may result
from the treatment of fractional shares as described below, each of our stockholders will hold the same percentage of our outstanding
common stock immediately following the Reverse Stock Split as such stockholder holds immediately prior to the Reverse Stock Split.

Reasons for Reverse Stock Split

To maintain our listing on The Nasdaq Capital Market. By
potentially having the effect of increasing our stock price, the Reverse Stock Split would reduce the risk that our common stock could
be delisted from The Nasdaq Capital Market. To continue our listing on The Nasdaq Capital Market, we must comply with Nasdaq Marketplace
Rules, which requirements include a minimum bid price of $1.00 per share.

On June 27, 2024, we received a notice, or Notice,
from Nasdaq, that we were not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market,
as set forth in Nasdaq Listing Rule 5550(a)(2), or the Minimum Bid Price Requirement. The Notice indicated that, consistent with Nasdaq
Listing Rule 5810(c)(3)(A), we had 180 days to regain compliance with the Minimum Bid Price Requirement by having the closing bid price
of our common stock meet or exceed $1.00 per share for at least ten consecutive business days. We subsequently requested an extension
of